Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Fuzheng Huayu Tablets in Post-COVID-19 Patients With Pulmonary Inflammation and Fibrosis : A Multicenter Double-blind Randomized Controlled Trial

NCT04279197 is registered in ClinicalTrials.gov with ShuGuang Hospital as lead sponsor.

NCT NCT04279197
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04279197 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Fuzheng Huayu Tablets in Post-COVID-19 Patients With Pulmonary Inflammation and Fibrosis : A Multicenter Double-blind Randomized Controlled Trial
Lead sponsor
ShuGuang Hospital
Phase
Phase 2
Overall status
Completed
Start date
April 23, 2020
Completion date
March 24, 2021
Enrollment
142 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary fibrosis due to covid-19